1. Home
  2. EOLS
  3. EOLS News

Latest Evolus Inc. (EOLS) News on June 2, 2025

AeroFlexx Awarded New Patents in Sustainable Packaging Innovation
EOLS

GlobeNewswire

7 hours ago

AeroFlexx Awarded New Patents in Sustainable Packaging Innovation

RBC and Pattison Food Group expand partnership to bring added convenience and everyday value to shoppers in Western Canada
EOLS

CNW Group

7 hours ago

RBC and Pattison Food Group expand partnership to bring added convenience and everyday value to shoppers in Western Canada

EOLS

PR Newswire

7 hours ago

TAE Technologies Raises $150 Million in Latest Funding Round

GoNetspeed Broadens Massachusetts Network on The Cape
EOLS

Business Wire

7 hours ago

GoNetspeed Broadens Massachusetts Network on The Cape

Endpoint Security Market worth $38.28 billion by 2030- Exclusive Report by MarketsandMarkets™
EOLS

PR Newswire

7 hours ago

Endpoint Security Market worth $38.28 billion by 2030- Exclusive Report by MarketsandMarkets™

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
EOLS

PR Newswire

7 hours ago

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

What are Akuvox's Latest Offerings that Cement its Leadership in Smart Intercoms?
EOLS

PR Newswire

7 hours ago

What are Akuvox's Latest Offerings that Cement its Leadership in Smart Intercoms?

Crush Colossal Kaiju with a Game-Changing Blow: KAIJU NO. 8 THE GAME Unveils Details for Original Story!
EOLS

PR Newswire

7 hours ago

Crush Colossal Kaiju with a Game-Changing Blow: KAIJU NO. 8 THE GAME Unveils Details for Original Story!

EOLS

MT Newswires

6 days ago

Evolus CFO Sandra Beaver Resigns

Evolus Announces Departure of its Chief Financial Officer
EOLS

Business Wire

6 days ago

Evolus Announces Departure of its Chief Financial Officer

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
EOLS

Business Wire

11 days ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

17 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS): A Bull Case Theory
EOLS

Insider Monkey

20 days ago

Evolus, Inc. (EOLS): A Bull Case Theory

Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
EOLS

Simply Wall St.

23 days ago

Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Evolus First Quarter 2025 Earnings: Misses Expectations
EOLS

Simply Wall St.

24 days ago

Evolus First Quarter 2025 Earnings: Misses Expectations

EOLS

Thomson Reuters StreetEvents

25 days ago

Q1 2025 Evolus Inc Earnings Call

Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
EOLS

GuruFocus.com

a month ago

Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
EOLS

Zacks

a month ago

Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates

Evolus Reports First Quarter 2025 Results
EOLS

Business Wire

a month ago

Evolus Reports First Quarter 2025 Results

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
EOLS

Business Wire

a month ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
EOLS

Zacks

a month ago

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus to Report First Quarter Financial Results on May 7, 2025
EOLS

Business Wire

a month ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

a month ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EOLS

MT Newswires

2 months ago

BTIG Initiates Evolus at Buy With $21 Price Target

Evolus Announces Commercial Launch of Evolysse™
EOLS

Business Wire

2 months ago

Evolus Announces Commercial Launch of Evolysse™

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
EOLS

Business Wire

2 months ago

Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
EOLS

Business Wire

2 months ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain
EOLS

Simply Wall St.

2 months ago

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

2 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EOLS

MT Newswires

2 months ago

Evolus Insider Sold Shares Worth $1,370,249, According to a Recent SEC Filing

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
EOLS

Motley Fool

3 months ago

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas

EOLS

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Evolus Inc Earnings Call

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...
EOLS

GuruFocus.com

3 months ago

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...

EOLS

MT Newswires

3 months ago

Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
EOLS

Zacks

3 months ago

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
EOLS

Business Wire

3 months ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?
EOLS

Insider Monkey

3 months ago

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
EOLS

Business Wire

3 months ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
EOLS

Business Wire

3 months ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
EOLS

Business Wire

3 months ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
EOLS

Zacks

4 months ago

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

EOLS

MT Newswires

4 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

EOLS

MT Newswires

4 months ago

Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
EOLS

Business Wire

4 months ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing
EOLS

Simply Wall St.

4 months ago

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?
EOLS

Zacks

4 months ago

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
EOLS

Investor's Business Daily

4 months ago

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

EOLS

MT Newswires

4 months ago

Evolus Reports Q4 Preliminary Net Revenue; Shares Rise Pre-Bell

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
EOLS

Business Wire

4 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

5 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability
EOLS

Simply Wall St.

5 months ago

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

6 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher
EOLS

Zacks

6 months ago

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
EOLS

Zacks

7 months ago

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
EOLS

Simply Wall St.

7 months ago

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Evolus Third Quarter 2024 Earnings: Misses Expectations
EOLS

Simply Wall St.

7 months ago

Evolus Third Quarter 2024 Earnings: Misses Expectations

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges
EOLS

GuruFocus.com

7 months ago

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
EOLS

Zacks

7 months ago

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus Reports Third Quarter 2024 Results
EOLS

Business Wire

7 months ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference
EOLS

Business Wire

7 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

EOLS

MT Newswires

7 months ago

Evolus Gains EU Approval for Estyme Hyaluronic Acid Fillers

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
EOLS

Business Wire

7 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Insulet (PODD) Earnings Expected to Grow: Should You Buy?
EOLS

Zacks

7 months ago

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
EOLS

Zacks

7 months ago

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
EOLS

Business Wire

7 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024
EOLS

Business Wire

7 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

8 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years
EOLS

Simply Wall St.

8 months ago

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
EOLS

GuruFocus.com

8 months ago

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

8 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
EOLS

Business Wire

9 months ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

10 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?
EOLS

Insider Monkey

10 months ago

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
EOLS

Simply Wall St.

10 months ago

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
EOLS

Zacks

10 months ago

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
EOLS

Investor's Business Daily

10 months ago

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
EOLS

Business Wire

10 months ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024
EOLS

Business Wire

10 months ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
EOLS

Business Wire

10 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
EOLS

Business Wire

10 months ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
EOLS

Pharmaceutical Technology

10 months ago

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Evolus to Report Second Quarter Financial Results on July 31, 2024
EOLS

Business Wire

a year ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors
EOLS

Business Wire

a year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

EOLS

MT Newswires

a year ago

Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
EOLS

Business Wire

a year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
EOLS

Simply Wall St.

a year ago

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
EOLS

Business Wire

a year ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
EOLS

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72
EOLS

GlobeNewswire

a year ago

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

Camber Energy Announces Passing of Director Lawrence Fisher
EOLS

ACCESSWIRE

a year ago

Camber Energy Announces Passing of Director Lawrence Fisher

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024
EOLS

Newsfile

a year ago

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

EOLS

GlobeNewswire

a year ago

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EOLS

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
EOLS

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS
EOLS

CNW Group

a year ago

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024
EOLS

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

EOLS

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 06/07/2024

The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space
EOLS

WWD

a year ago

The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
EOLS

Zacks

a year ago

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
EOLS

Business Wire

a year ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Share on Social Networks: